share_log

Stephens & Co. Reiterates Overweight on MaxCyte, Maintains $12 Price Target

Benzinga ·  Mar 28, 2023 07:26

Stephens & Co. analyst Jacob Johnson reiterates MaxCyte (NASDAQ:MXCT) with a Overweight and maintains $12 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment